Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 272.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -258.03M |
| Shares Out | 107.74M |
| EPS (ttm) | -2.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,033,617 |
| Open | 2.580 |
| Previous Close | 2.590 |
| Day's Range | 2.500 - 2.695 |
| 52-Week Range | 2.190 - 26.980 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 18.50 (+631.23%) |
| Earnings Date | Aug 4, 2025 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 631.23% from the latest price.
News
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Opt...
Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Com...
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Com...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Com...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals Inc RCKT on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp...
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the cl...
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the cl...
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseas...